PHOTO
Two significant technologies unveiled at Arab Health Exhibition & Congress 2016 that will assist healthcare professionals and drive standards in patient care
Dubai, UAE - Roche Diagnostics Middle East (RDME), the leading in in-vitro diagnostics in the region, unveiled two major new diagnostic technologies at the Arab Health Exhibition & Congress 2016. These new innovative instruments will further enable the region's health care professionals and patients to make timely decisions upon receiving utmost accurate diagnosis.
Commenting on RDME's participation in the Arab Health Exhibition & Congress 2016, Moritz Hartmann, General Manager of RDME said: "Arab Health Exhibition & Congress provides the perfect launch pad for these innovative instruments, as diagnostics have become one of the most influential elements in healthcare provision. That's why we strive through our continuous innovation to constantly increase testing efficiency, workflow integration, and breadth of diagnosis - enabling labs to provide test results while increasing accuracy and speed, thus empowering healthcare professionals and their patients to make informed decisions that are appropriate for them and their treatment journey."
The newly launched cobas e 801 module for immunology testing is a platform capable of carrying out double the number of tests compared with the previous versions e 601 and e 602, within the same laboratory space. The system requires smaller blood samples, making it particularly suitable for the diagnosis of vulnerable patients such as newly born babies, those with cancer, and the elderly.
RDME also showcased the cobas c 513 - a high-throughput HbA1c analyzer - which can assess sugar levels for the last three months, making it suitable for diagnosis and monitoring for diabetes patients. Recent figures from the International Diabetes Federation show that almost 37 million people in the MENA region have diabetes, which if left unchecked could more than double by 2035.1
"The increasing number of people with diabetes is challenging healthcare providers and is putting a significant strain on healthcare systems," Mr. Hartmann said. "With the cobas c 513, Roche Diagnostics is meeting the growing testing needs of our customers here in the Middle East and ultimately improving patient care," he added.
The highly automated analyzer sets new standards in terms of laboratory efficiency and reduces the risk of contamination while increasing safety for laboratory personnel. Designed to run a large number of tests simultaneously, the cobas c 513 also features direct results reporting, thereby minimizing the risk of result misinterpretation and eliminating the need to perform pre-analyses procedures. This saves valuable time while ensuring high quality results.
As the leading medical diagnostics company in the region, Mr. Hartmann reaffirmed RDME's commitment to support the community through several educational initiatives that aim at raising awareness, such as Roche Academy, several online educational courses, in addition to 'MeDia Talks', an educational program that engages members of the media throughout the region. The company is also the diamond sponsor of MEDLAB, the technology component of Arab Health.
-Ends-
Reference
1. IDF Diabetes Atlas. Sixth edition. www.idf.org/diabetesatlas Last accessed 6th January 2016
About Roche Diagnostics Middle East
Roche have taken the unprecedented move of being the first IVD company to have a Management Center and a logistics hub in the Middle East. Roche has extended its ownership of the entire supply chain, quality control and customer support all the way into the centre of the region. This base of operations reinforces the commitment to global Roche standards and is driven by a full team of vastly experienced specialists offering a complete portfolio of services. With this regional empowerment, Roche has moved its leadership and decision-making closer to its customers and distributors. These investments allow Roche Diagnostics Middle East to develop from being a supplier into becoming the preferred IVD partner for its customers.
Roche Diagnostics Middle East offers a complete portfolio of services in 16 countries: UAE, Saudi Arabia, Iraq, Iran, Qatar, Kuwait, Bahrain, Oman, Yemen, Syria, Jordan, Palestine, Lebanon, Egypt, Libya and Maldives. For more information, please visit roche-middleeast.com
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit roche.com.
All trademarks used or mentioned in this release are protected by law.
PR Contact:
Hill+Knowlton Strategies
Natasha Tinston
Natasha.Tinston@hkstrategies.com
M: +971 5 0708 3353
© Press Release 2016
